Investor Alert

Market Pulse Archives

June 30, 2020, 8:13 a.m. EDT

Inovio's stock falls as it discloses early-stage data for its COVID-19 vaccine candidate

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Inovio Pharmaceuticals Inc. (INO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Inovio Pharmaceuticals Inc. /zigman2/quotes/202993817/composite INO -4.26% tumbled 10.8% in premarket trading on Tuesday after the company said its COVID-19 vaccine candidate was considered safe and well-tolerated in all 40 of the participants in a Phase 1 clinical trial. However, the company did not disclose data about the participants' antibody response, though it said 94% of 36 trial participants showed "overall immunological response rates based on preliminary data assessing humoral (binding and neutralizing) and T cell immune responses." (Three trial participants tested positive for COVID-19 and one left the study for non-clinical reasons.) There were some adverse events, though none were serious, that primarily consisted of redness on the skin where the experimental vaccine was administered. Inovio also said it has added older participants to the early-stage trial; the original 40 are between the ages of 18 and 50 years old. It also plans to start a Phase 2/3 study this summer. Inovio is one of a handful of companies in the U.S. studying whether their experimental vaccines can prevent infection with the coronavirus. Shares of Inovio have soared 860.3% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.11% declined 5.5% since the start of the year.

US : U.S.: Nasdaq
$ 6.74
-0.30 -4.26%
Volume: 4.07M
Oct. 22, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.48 billion
Rev. per Employee
-4.88 -0.11%
Volume: 1.82B
Oct. 22, 2021 5:04p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.